Quantcast
Last updated on April 20, 2014 at 1:20 EDT

Latest H5N1 clinical trials Stories

2013-03-26 12:29:23

Team will develop and manufacture GSK's next generation influenza vaccines to protect the nation against global pandemics AUSTIN, Texas and PHILADELPHIA, March 26, 2013 /PRNewswire/ -- GlaxoSmithKline plc (GSK) and The Texas A&M University System announced today that the U.S. Department of Health and Human Services (DHHS) has approved the establishment of a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and...

2013-03-14 08:28:20

- Unblinded Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of 95.4% BEIJING, March 14, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease ("HFMD"). The primary objective of the study was to...

2013-01-23 11:18:45

A candidate dengue vaccine developed by scientists at the National Institutes of Health (NIH) has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to results from an early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The trial results were published online on January 17 in the Journal of Infectious Diseases. Dengue fever, prevalent in many tropical and subtropical...

FDA Approves Flublok Flu Vaccine
2013-01-17 19:32:51

Lee Rannals for redOrbit.com — Your Universe Online A new flu vaccine won regulatory approval on Wednesday and its limited supplies are expected to be available this winter. Protein Sciences won the approval for Flublok, which is made with a process that does not require the virus to be grown in chicken eggs. “This approval represents a technological advance in the manufacturing of an influenza vaccine,” Dr. Karen Midthun, a senior official at the U.S. Food and...

2013-01-16 20:21:40

MERIDEN, Conn., Jan. 16, 2013 /PRNewswire/ -- The U.S. FDA approved Flublok for people 18-49 years old - making it the first recombinant vaccine for influenza available on the market. Approval for all people 18 years and above is expected later in 2013. Flublok features: First influenza vaccine made without the use of live influenza virus First egg-free influenza vaccine Highly purified without preservatives (thimerosal), antibiotics or adjuvants Three times the active ingredient...

2012-12-10 04:21:32

BLUE BELL, Pa., Dec. 10, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) reported interim results of a phase I trial that showed that a single dose of its H1N1 universal SynCon® flu vaccine followed with a dose of a seasonal flu vaccine generated protective immune responses in 40% of trial subjects compared with a 20% response rate in elderly patients who received the seasonal flu vaccine alone. This interim data is a significant step in developing a more effective flu...

2012-11-25 12:20:14

TUEBINGEN, Germany, Nov. 25, 2012 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases. In vivo data published by...

2012-10-22 11:25:37

NES ZIONA, Israel, October 22, 2012 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) today announced that the Company has passed successfully a 2 day QP GMP audit during which the Company`s manufacturing facility, production process, personnel and quality control procedures were examined in great detail. This demanding certification is a requirement for Companies intending to manufacture a clinical grade product for human trials anywhere in Europe and gives the Company...

2012-10-22 07:30:26

SWIFTWATER, Pa., Oct. 22, 2012 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV). Three clinical trials have been conducted to evaluate the safety and the immune response to the quadrivalent influenza vaccine in children, adults and the elderly. All three studies demonstrated that the safety and immunogenicity profiles...

2012-10-18 07:26:23

SWIFTWATER, Pa., Oct. 18, 2012 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for a quadrivalent formulation of its Fluzone(® ) (Influenza Virus Vaccine). The sBLA file has been accepted by the FDA for full review, and an action date is anticipated in the second quarter of 2013. "The...